VEGFA and neoplasm: Bevacizumab (Avastin; Genentech, San Francisco, CA, USA), a monoclonal antibody that inhibits VEGF, results in tumor shrinkage in 55% of patients with recurrent glioblastomas, palliating neurological symptoms and increasing progression-free survival [50].